IRIS
PICCIN, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.500
EU - Europa 446
AS - Asia 231
OC - Oceania 1
Totale 2.178
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.497
CN - Cina 174
DE - Germania 124
UA - Ucraina 116
GB - Regno Unito 58
TR - Turchia 51
BE - Belgio 32
SE - Svezia 30
FI - Finlandia 27
IT - Italia 27
RU - Federazione Russa 16
FR - Francia 8
CA - Canada 3
CZ - Repubblica Ceca 3
IE - Irlanda 2
IN - India 2
IR - Iran 2
NL - Olanda 2
AU - Australia 1
BD - Bangladesh 1
KZ - Kazakistan 1
RO - Romania 1
Totale 2.178
Salva come PNG Salva come JPEG
Città #
Woodbridge 277
Fairfield 160
Jacksonville 134
Chandler 129
Houston 129
Ann Arbor 89
Seattle 68
Ashburn 67
Wilmington 60
Cambridge 54
Beijing 50
Addison 45
Izmir 43
Nanjing 38
Brussels 32
Princeton 26
Milan 22
Boardman 21
San Diego 19
Dearborn 16
Shenyang 15
Kunming 11
Jiaxing 8
Guangzhou 7
Hebei 7
Jinan 7
Nanchang 7
Changsha 6
Norwalk 6
San Mateo 6
Leawood 5
Mountain View 5
Redwood City 5
Des Moines 4
Falls Church 4
Tappahannock 4
Tianjin 4
Washington 4
Hangzhou 3
Monmouth Junction 3
Montréal 3
Munich 3
Prescot 3
Acton 2
Ardabil 2
Augusta 2
Brno 2
Dublin 2
Hefei 2
Helsinki 2
New York 2
Philadelphia 2
Taizhou 2
Verona 2
Almaty 1
Bremen 1
Changchun 1
Delhi 1
Dhaka 1
Ferrara 1
Hanover 1
Jinhua 1
Lappeenranta 1
Mcallen 1
Messina 1
Mumbai 1
Ningbo 1
Shanghai 1
Yellow Springs 1
Zhengzhou 1
Totale 1.647
Salva come PNG Salva come JPEG
Nome #
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 142
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 137
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 135
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 130
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. 112
null 106
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 104
miR-15a and miR-16-1 down-regulation in pituitary adenomas 101
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 101
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 100
Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. 97
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro 93
SHP-1 restrains cell proliferation in human medullary thyroid carcinoma 83
Role of complex Cdk4/Cyclin D1 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro 83
Antiproliferative effects of somatostatin analogs in pituitary adenomas 80
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. 80
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 77
Chemoresistance of Medullary thryroid carcinoma cells is reversed by COX-2 inhibitors in vitro through a PGE2-dependent mechanism 63
Role of complex cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro 62
Selective Cyclo-oxygenase 2 inhibitors revert chemoresistance In Medullary thyroid carcinoma by a mechanism mediated by P-gp and PGH2 62
Somatostatin analogs in vitro effects in a growth hormone-releasing hormone (GHRH)-secreting bronchial carcinoid 60
Somatostatin inhibits a medullary thyroid carcinoma cell line growth by activating SHP-1 59
SSTR subtypes expression pattern influences the antiproliferative effects of somatostatin and lanreotide on human medullary thyroid carinomas in vitro 55
Somatostatin differentially influences proliferation and gene expression by modulating SHP-1 and cAMP pathways in a human medullary thyroid carcinoma cell line 54
Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro 15
Totale 2.191
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.298
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019292 0 0 0 0 0 1 41 6 26 46 60 112
2019/2020502 74 16 20 60 42 60 43 54 37 54 35 7
2020/2021281 33 29 8 32 12 28 11 31 6 33 48 10
2021/2022320 10 39 31 6 18 12 16 11 10 20 32 115
2022/2023288 27 24 22 35 36 45 27 17 33 4 12 6
2023/202483 18 29 5 9 18 4 0 0 0 0 0 0
Totale 2.191